Jacobson Pharma Corporation Limited (HKG:2633)

Market Cap	2.09B -30.1%
Revenue (ttm)	1.57B -0.5%
Net Income	301.62M +0.3%
EPS	0.15 -0.3%
Shares Out	2.00B
PE Ratio	6.92
Forward PE	6.61
Dividend	0.09 (8.74%)
Ex-Dividend Date	Sep 7, 2026

Volume	214,000
Open	1.050
Previous Close	1.045
Day's Range	1.045 - 1.050
52-Week Range	0.980 - 1.530
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 19, 2026

About HKG:2633

Jacobson Pharma Corporation Limited, through its subsidiaries, engages in the development, production, marketing, and sale of essential medicines and specialty drugs in Hong Kong, Mainland China, Macau, and internationally. The company offers a portfolio of generic drugs for various therapeutic classes, such as cardiovascular, central nervous, gastrointestinal, respiratory, musculo-skeletal, genito-urinary, anti-infectives, endocrine and metabolic, dermatologicals, and anti-allergics in oral solid and liquid, external liquid, semi-solid, steril...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 1,768
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2633

Financial Performance

In fiscal year 2026, HKG:2633's revenue was 1.57 billion, a decrease of -0.47% compared to the previous year's 1.58 billion. Earnings were 301.62 million, an increase of 0.26%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error